TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* successful coronary intervention \< 14 days~* regional contraction deficit of the left ventricle as detected either by echocardiography or cardiacMRI~* globally reduced ejection fraction (cardiac MRI or echocardiography: \< 60%)~* willing and able to cooperate~* voluntary participation~Exclusion Criteria:~* contraindication for cardiac MRI (i.e. pacemaker, ICD current or within the next 6 months, other metal implants)~* cardiogenic shock at time of inclusion~* uncontrolled hypertension (systolic blood pressure \> 180mmHg)~* hemoglobin \> 16mg/dl~* thrombocytosis~* malignant tumor~* missing informed consent~* renal failure (creatinine \> 300 mg/dl)~* liver failure~* other prognosis limiting, severe diseases (i.e. dementia)~* indication for open label erythropoietin treatment~* allergy towards solvents of the EPO preparation~* woman of childbearing potential~* other clinical study within the preceding 30days~* known alcohol or drug abuse~* neurologic or psychiatry disorders~* previous organ transplantation

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
- 2 (Type: PLACEBO_COMPARATOR): Placebo to erythropoetin beta.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.~* During the 28 day screening period, subjects must adequately complete the headache eDiary and must have headaches occurring on ≥ 15 to ≤ 26 days of which at least 8 must be migraine days.~* Headache eDiary was completed on at least 24 of the 28 days prior to randomization.~Exclusion Criteria:~* Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).~* Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded.~* Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections within 4 months prior to screening and during the screening period.~* History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.~* Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.~* Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALD403 (Eptinezumab) Dose Level 1 (Type: EXPERIMENTAL): ALD403 (Eptinezumab) Dose Level 1 (IV)
- ALD403 (Eptinezumab) Dose Level 2 (Type: EXPERIMENTAL): ALD403 (Eptinezumab) Dose Level 2 (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 to 65 years (inclusive) with a clinical history of seasonal allergic rhinitis (SAR) (for at least 2 years) and exhibiting a positive skin prick test~Exclusion Criteria:~* Pregnant or lactating women~* Patients with known hypersensitivity to any of the components of the formulation~* Patients with a history of seasonal asthma during ragweed season.~* Patient requiring chronic use of inhaled or systemic corticosteroids~* Patients with perennial rhinitis; non-allergic rhinitis; or ocular infection within 3 weeks before the screening~* Patients with history of acute or significant chronic sinusitis or chronic purulent post-nasal drip or Rhinitis Medicamentosa as determined by the Investigator.~* Patients with history of narrow-angle glaucoma, increased intraocular pressure, posterior subcapsular cataract, urinary retention, uncontrolled hypertension, severe Coronary Artery Disease, Ischemic Heart Disease, uncontrolled Diabetes Mellitus, Hyperthyroidism, Renal Impairment or Prostatic Hypertrophy, and those receiving MAO inhibitor therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo nasal spray (Type: PLACEBO_COMPARATOR): Placebo nasal spray - 2 sprays per nostril, BID
- Molo 1 (also referred as GSP 301-2 NS) (Type: EXPERIMENTAL): Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
- Molo 2 (also referred as GSP 301-1 NS) (Type: EXPERIMENTAL): Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
- DYMISTA nasal spray (Type: ACTIVE_COMPARATOR): Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
- PATANASE nasal spray (Type: ACTIVE_COMPARATOR): Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ProQuad® Intramuscular vs Subcutaneous

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participant of either gender,~* Age 12 to 18 months,~* Negative clinical history of measles, mumps, rubella, varicella and zoster,~* Consent form signed by both holders of the parental authority or by the legal representative~* Holder(s) of the the parental authority / legal representative able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~* Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination,~* Any recent (≤30 days) exposure to measles, mumps, rubella, varicella and/or zoster~* Any recent (≤3 days) history of febrile illness~* Any severe chronic disease,~* Active untreated tuberculosis,~* Known personal history of seizure disorder,~* Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems,~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~* Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity including those resulting from corticosteroid \[any long-term (≥14 days) administration of systemic corticosteroid therapy given daily or on alternate days at high doses (≥2 mg/kg/day prednisone equivalent or ≥20 mg/day if weight more than 10 kg) within the previous 30 days\] or other immunosuppressive therapy,~* Any previous (≤ 150 days) receipt of immune globulin or any blood-derived product or scheduled to be administered through Visit 3,~* Any recent (≤7 days) tuberculin test or scheduled tuberculin test through Visit 3,~* Any recent (≤30 days) receipt of an inactivated or a live vaccine or scheduled vaccination through Visit 3,

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Intramuscular ProQuad® (Type: EXPERIMENTAL): Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
- Subcutaneous ProQuad® (Type: ACTIVE_COMPARATOR): Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meibomian gland dysfunction~* Dry Eye symptoms~Exclusion Criteria:~* Ocular surgery, ocular injury or ocular Herpes infection within past 3 months~* Active ocular infection~* Active ocular inflammation or recurrent inflammation within past 3 months~* Moderate to severe allergic conjunctivitis~* Severe eyelid inflammation~* Eyelid abnormalities that affect lid function~* Ocular surface abnormalities that may compromise corneal integrity~* Systemic disease conditions or medications that cause dry eye~* Use of other treatments for meibomian gland dysfunction or dry eye~* Pregnant or nursing women~* Participation in another ophthalmic clinical trial within past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LipiFlow Treatment (Type: EXPERIMENTAL): Treatment with LipiFlow device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* MPH naïve~* recent ICD-10 diagnosis of hyperkinetic disorder (F90.0-90.9) or attention deficit disorder without hyperactivity (F98.8)~* clinical indication for treatment with IR-MPH~Exclusion Criteria:~* mental retardation (ICD-F70.X or IQ \< 70)~* previous treatment with drugs metabolised by carboxylesterase 1 (CES1)~* severe comorbid psychiatric or somatic disease that resulted in contraindication for treatment with MPH~* language barriers~* lack of informed consent.~Specific additional exclusion criteria for genetic analyses:~* Non-caucasian~* Lack of DNA~* Consanguine patients~* Variants with a minor allele frequency (MAF) above 0.05 or not in Hardy-Weinberg equilibrium

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- ADHD patients (Type: None): Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benfotiamine in Alzheimer's Disease: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years of age or older~* Clinical diagnosis of AMCI by the Peterson criteria or probable AD dementia according to the National Institute of Neurological Disorders and stroke and the Alzheimer's Disease related Disorders Association (NINCDS/ADRDA)~* MMSE score \> or equal to 21~* CDR score \> or equal to 0.5 and \< or equal to1~* Cornell Scale for Depression in Dementia(CSDD) score \<10.~* Ambulatory or ambulatory with aide~* Have a caregiver willing to accompany the patient to each visit, accept responsibility for supervising treatment and provided input to clinical outcome assessments~* Reside at home~* Speak English~* Amyloid positive PET-scan~* If they are on AD medications they must be stable on AD medications for at least three months prior to baseline~* Subjects ore willing/able to provide informed consent.~Exclusion Criteria:~* Patients with significant neurological disorder other than AD including hypoxia, stroke, traumatic brain injury~* A current psychiatric disorder according the DSM-IV diagnosis of major depression unless successfully treated on a stable dose of an antidepressant for at least 4 weeks and continues on stable dose throughout the study~* Any other DSM-IV Axis l diagnosis including other primary neurodegenerative dementia schizophrenia or bipolar depression~* A current diagnosis of uncontrolled diabetes mellitus (glucose values \> 200 mg/ml).~* Patients with uncontrolled diabetes will be excluded because high glucose will alter the FDG-PET studies. The clinic that does PET (Columbia University Medical Center) excludes patients if glucose values exceed 200 mg/ml.~* A current diagnosis of active, uncontrolled seizure disorder~* A current diagnosis of probable or possible vascular dementia according to NINDS-AIREN~* An investigational drug during the previous 4 weeks~* A current diagnosis of severe unstable cardiovascular disease~* A current diagnosis of acute severe, or unstable asthmatic condition (e.g., severe chronic obstructive pulmonary disease (COPD),~* A current diagnosis of cardiac, renal or hepatic disease~* History of alcoholism, current or within past 5 years~* A disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulty)~* A1C less than or equal to 8~* Current diagnosis of cancer/active treatments

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Benfotiamine (Type: EXPERIMENTAL): The patients in this arm will be treated with benfotiamine
- Placebo (Type: PLACEBO_COMPARATOR): The patients in this arm will be treated with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women,~* Experiencing one symptom of vaginal atrophy (vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity or vaginal bleeding associated with sexual activity,~* Women having a low maturation index and a vaginal pH above 5,~* Endometrial thickness of 4 mm or less at transvaginal ultrasonography,~* Body weight within 18.5 and 32.0 according to body mass index.~Exclusion Criteria:~* Undiagnosed abnormal genital bleeding,~* Active or history of thromboembolic disease,~* Significant metabolic or endocrine disease,~* Significant complication on previous hormonal therapy,~* Use of hormonal implants within 6 months prior to study entry,~* Use of oral estrogen, progestin or DHEA in the 8 weeks prior to baseline,~* Use of natural (phytoestrogens) or herbal products in the 2 weeks prior to baseline,~* Chronic use of corticosteroids,~* Hypertension not controlled by standard therapy.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo suppository; once daily for 7 days.
- DHEA 0.50% (Type: EXPERIMENTAL): DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
- DHEA 1.0% (Type: EXPERIMENTAL): DHEA 1.0% (13 mg) suppository; once daily for 7 days.
- DHEA 1.8% (Type: EXPERIMENTAL): DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* newly-diagnosed AML~* either poor risk cytogenetics and/or bad response to the first cycle of IC defined by more than 10% marrow blasts on day 15~* HLA-compatible donor (maximum one HLA-antigen mismatch)~Exclusion Criteria:~* no donor~* Age \< 16 years \> 75 years~* Cardiac insufficiency requiring treatment or symptomatic coronary artery disease~* Hepatic disease, with AST \> 2 times normal~* Severe hypoxemia , pO2 \< 70 mm Hg, with decreased DLCO \< 70% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 60% of predicted~* Impaired renal function (creatinine \> 2 times normal or creatinine clearance \< 50% for age, weight, height)~* HIV-positive patients due to risk of reactivation or acceleration of HIV replication~* Female patients who are pregnant or breast feeding due to risks to fetus from conditioning regimen and potential risks to nursing infants~* Life expectancy severely limited by diseases other than malignancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of Study OTX-101-2016-001~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OTX-101 0.09% (Type: EXPERIMENTAL): 0.09% cyclosporine nanomicellar solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete